CHICAGO — An experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread, by 65%, compared to immunotherapy treatment alone, the companies reported on Monday.
The results, presented at the American Society of Clinical Oncology meeting in Chicago, follow earlier promising data from the trial showing the customized mRNA…